SLAMF7 (also known as CS1 or CD319 or CRACC) is a hemophilic single pass type I transmembrane protein belonging to the SLAM (signaling lymphocytic activation molecule) family of receptors. It serves as a receptor on immune cells, including natural killer (NK) cells and may play a role in lymphocyte adhesion. SLAMF7 mediates NK cell activation through a SAPindependent extracellular signal-regulated ERK-mediated pathway and also involved in phagocytosis of hematopoietic tumor cells independent of signaling lymphocyte activation molecule-associated protein (SAP) adaptors. SLAMF-7 is expressed in spleen, lymph node, bone marrow, appendix, small intestine, stomach, lung, trachea, peripheral blood leukocytes, on natural killer (NK) cells, T cells, multiple myeloma cells and stimulated B cells.
| Intended Use | IVD |
|---|---|
| Antibody Type | Membrane |
| Clone | SLAMF7/3649 |
| Source | Mouse |
| Tissue Type/Cancer Type | Tonsil tissue |
| Pack | 1 mL – Manual – Concentrate, 0.5 mL – Manual – Concentrate, 6 mL – Manual – RTU, 10 mL – Manual – RTU, 50 Tests – Automation – Xmatrx, 50 tests – NanoVIP, 160 Tests – Automation – Xmatrx |
